Vertex Pharmaceuticals Incorporated — 2023 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2023, with comparisons to 2022 and 2021. Vertex is a specialty-market biotechnology company. Its four marketed cystic fibrosis (CF) medicines generated all 2023 product revenue; CASGEVY, approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in several markets late in 2023, was beginning its commercial launch. The company operates in one pharmaceutical segment.
Key financial metrics
| Metric | 2023 | 2022 | Change / note |
|---|---|---|---|
| Revenue | $9.869 billion | $8.931 billion | Up 11% |
| Operating income | $3.832 billion | $4.307 billion | Down 11% |
| Net income | $3.620 billion | $3.322 billion | Up 9% |
| Diluted EPS | $13.89 | $12.82 | Up about 8% |
| Operating cash flow | $3.537 billion | $4.130 billion | Down 14% |
| Cash, cash equivalents and marketable securities | $13.716 billion | $10.891 billion | Up 26% |
| Working capital | $10.597 billion | $10.493 billion | Broadly stable |
Approximate 2023 margins: gross margin 87% (revenue less cost of sales); operating margin 39%; net margin 37%. Cost of sales was 13% of product revenue, versus 12% in 2022. The effective tax rate was 17.4%, versus 21.5%.
TRIKAFTA/KAFTRIO revenue was $8.945 billion, up 16%, and represented about 91% of total revenue. KALYDECO revenue fell 14% to $475.5 million; ORKAMBI fell 36% to $326.0 million; SYMDEKO/SYMKEVI fell 32% to $123.0 million. The declines were primarily attributed to patients switching to TRIKAFTA/KAFTRIO. U.S. revenue rose 6% to $6.040 billion; ex-U.S. revenue rose 18% to $3.829 billion.
R&D expense increased 25% to $3.163 billion, acquired in-process R&D expense rose to $527.1 million from $115.5 million, and SG&A increased 20% to $1.137 billion. Total operating costs and expenses grew 31% to $6.037 billion. Higher investment in development, business-development payments and launch preparation contributed to the increase. Interest income rose to $614.7 million from $144.6 million, supporting net income despite lower operating income.
Cash flow from investing activities was negative $3.142 billion, mainly reflecting net purchases of available-for-sale debt securities; financing cash flow was negative $562.2 million, including $427.6 million of share repurchases. The $500 million revolving credit facility was undrawn at year-end, with no principal or interest outstanding. Total liabilities were $5.150 billion; these included $808.4 million in present-value finance and operating lease liabilities. The company reported $13.7 billion in cash, cash equivalents and marketable securities and said available liquidity plus expected product-sale cash flows should fund operations for at least 12 months.
Material changes and notable items
- Revenue growth was driven by TRIKAFTA/KAFTRIO uptake, younger-age label expansions and ex-U.S. access. 2023 net product revenue did not include a material CASGEVY contribution.
- Operating income declined despite revenue growth, chiefly amid sharply higher acquired R&D charges and increased R&D and commercial spending.
- R&D and acquired R&D spending totaled about $3.690 billion. Significant 2023 business-development charges included payments to Entrada and CRISPR and a Septerna asset acquisition.
- CASGEVY’s FDA approval triggered a $200 million milestone payable to CRISPR, recorded as an intangible asset and current liability at year-end; the company also recorded a net $30 million intangible asset for an Editas sublicense.
- Share repurchases totaled $427.6 million in 2023; $2.6 billion remained under the $3.0 billion authorization at year-end. Vertex has never paid a cash dividend and does not anticipate one in the foreseeable future.
Outlook, management commentary and principal risks
- Management expects CF revenue to increase in 2024, citing continued TRIKAFTA/KAFTRIO performance, label expansions and broader access; the filing does not provide a specific 2024 revenue forecast.
- Management described 2024 as a foundational year for CASGEVY, as it activates treatment centers, builds reimbursement pathways and prepares for initial patient treatments. Uptake depends on complex cell collection, manufacturing and treatment logistics, center capacity, and adequate reimbursement.
- After positive Phase 3 results announced in February 2024, Vertex planned global filings by mid-2024 for once-daily vanzacaftor/tezacaftor/deutivacaftor for CF. The filing also reports plans to submit an NDA for VX-548 in acute pain by mid-2024, following positive Phase 3 results announced in January 2024. Both remain subject to regulatory review and approval.
- VX-548 also showed positive Phase 2 results in diabetic peripheral neuropathy; pivotal development was planned for 2024. Inaxaplin was expected to enter the Phase 3 portion of its Phase 2/3 trial in early 2024.
- The VX-880 type 1 diabetes trial was on a protocol-specified pause pending independent monitoring committee and regulator review after two patient deaths, which investigators determined were unrelated to VX-880. This pause and review remain important development uncertainties.
- Key business risks include heavy dependence on CF revenue and TRIKAFTA/KAFTRIO, competition, pricing and reimbursement pressure, clinical and regulatory uncertainty, cell-therapy adoption and manufacturing complexity, and reliance on third-party suppliers. McKesson accounted for 26% of gross product revenue in 2023.
- Other matters to monitor include $615.9 million of unrecognized tax benefits, including significant intercompany transfer-pricing exposures; currency movements; and intellectual-property uncertainty around CRISPR/Cas9. The company reported no material legal proceedings. KALYDECO generic litigation against Lupin concerning granules remained pending, with trial scheduled for April 2025; several other KALYDECO generic cases were settled confidentially.
Important facts for investors to verify
- Subsequent quarterly filings: whether 2024 CF revenue growth and any new-product contribution support management’s outlook.
- CASGEVY: patient starts, treatment-center activation, manufacturing turnaround and capacity, payer coverage, reimbursement terms, and recognized revenue or shared collaboration economics.
- Regulatory and clinical milestones: filing and review timing for the new CF combination and VX-548, and developments in VX-880’s pause and review.
- Revenue concentration and net pricing: TRIKAFTA/KAFTRIO performance, patient switching, ex-U.S. reimbursement, and exposure to major distributors and payors.
- Cash generation and spending: operating cash flow, R&D and acquired R&D charges, share repurchases, and whether liquidity remains consistent with planned launches and investment.
- Tax and intellectual-property developments, including transfer-pricing audits and CRISPR/Cas9 patent proceedings.